NASDAQ · Biotechnology · USD
Protara Therapeutics, Inc. (TARA) Stock Analysis
Protara Therapeutics, Inc. (TARA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TARA Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.57
- Previous Close
- $2.56
- Day's Range
- 2.49–2.61
- 52-Week Range
- 2.30–7.82
- Volume
- 971.15K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.47
Valuation
- Market Cap
- $147.74M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.36
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$57.44M
- Shares Outstanding
- 59.10M
- 1-Year Return
- −53.70%
Dividend and dates
- Earnings Date
- November 10, 2026estimated
- Avg Volume
- 891.59K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, TARA closed at $2.50, −53.70% over 1 year.
Protara Therapeutics, Inc. (TARA) has a market capitalization of $147.74M.
In fiscal 2025, TARA reported revenue of $0.00.
TARA Stock Return by Calendar Year
Protara Therapeutics, Inc. (TARA) 10-year return: what $10,000 became
- 1 year
- $10,000 $4,630
- −53.70%
- 5 years
- $10,000 $3,546
- −64.54%
- 10 years
- $10,000 $67
- −99.33%
If you had invested $10,000 in Protara Therapeutics, Inc. (TARA) 10 years ago, at the close on October 21, 2016, it would have been worth $67 at the close on October 21, 2026: −99.33% in total, −39.41% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −53.10% |
| 2025 | +0.95% |
| 2024 | +181.60% |
| 2023 | −30.04% |
| 2022 | −60.30% |
| 2021 | −72.12% |
| 2020 | +47.62% |
| 2019 | −81.94% |
| 2018 | +19.47% |
| 2017 | +0.00% |
| 2016 (partial year) | −76.97% |
As of October 21, 2026.
TARA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$57.44M | — |
| 2024 | $0.00 | −$44.60M | — |
| 2023 | $0.00 | −$40.42M | — |
| 2022 | $0.00 | −$65.95M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$64.55M | −$57.44M | — |
| 2024 | $0.00 | — | −$49.15M | −$44.60M | — |
| 2023 | $0.00 | — | −$43.61M | −$40.42M | — |
| 2022 | $0.00 | — | −$37.55M | −$65.95M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
YahooProtara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
YahooProtara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
BenzingaProtara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B